Gap Analysis Critical for Combination Product cGMPs

The GMP Letter
A A
To comply with FDA’s combination product good manufacturing practices, both devicemakers and drugmakers should first look at their systems and conduct a gap analysis using both the quality system regulation and drug cGMPs.

To View This Article:

Login

Subscribe To The GMP Letter

Buy This Article Now

Add this article to your cart for $40.00